Sponsored Links
| Blinatumomab Achieved 75% Complete Remission In Acute Relapsing Lymphoblastic Leukemia Patients |
 |
 |
 |
| Medical News - Hematology | |||
|
75% of acute lymphoblastic leukemia patients who had relapsed after standard therapy achieved complete remission with blinatumomab, a medication designed to harness T cells that destroy cancer cells. Blinatumomab makers, Micromet says the drug is "the most advanced of a new class of agents called BiTE® antibodies... Read more: Blood / Hematology News From Medical News Today
|